Catheter ablation of atrial fibrillation in transthyretin and light-chain cardiac amyloidosis: results from the multicentre AMYL-AF study
Europace · 02.06.2026 · 28 (6)
DOI: 10.1093/europace/euag143 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Europace, online erschienen am 29.06.2026. Verfasst von Daniele Faccenda und 42 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, Lugano CH-6900, Switzerland. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Atrial Fibrillation, Cardiomyopathies, Catheter Ablation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Atrial fibrillation (AF) is highly prevalent among cardiac amyloidosis (CA) patients and contributes significantly to their morbidity and mortality. Evidence regarding AF ablation efficacy and safety in CA patients remains limited. The aim of our study is to evaluate baseline characteristics, clinical course and outcomes of AF ablation in a series of patients with transthyretin (ATTR) or light-chain (AL) CA from a multicentre international registry. Methods and results Patients with CA who underwent AF ablation were included. Co-primary endpoints were: (i) atrial arrhythmia (AA) recurrence; (ii) a composite endpoint of all-cause mortality and heart failure hospitalization (HFH). 109 patients (mean age 72.4 ± 7.4 years, females 17.4%, persistent AF 64.2%, ATTR 78%, AL 22%) were included. Radiofrequency, cryo-balloon and pulsed-field ablation were performed in 67%, 15% and 18% of patients, respectively; 49.5% received pulmonary vein isolation plus additional ablations. Low voltage zones were documented in 34 out of 44 patients undergoing electro-anatomical mapping (77.3%). During a median follow-up of 22.7 months, 63 patients (58.3%) experienced AA recurrence (32.4% persistent AF recurrence), with no significant differences between CA subtypes (ATTR 59.5% vs. AL 54.2%, log-rank P = 0.55). The composite endpoint of HFH and all-cause death occurred in 27 patients (25%). Recurrence of persistent AF was associated with three-fold higher risk (OR 2.9, P = 0.02) of the composite endpoint.
Conclusion
CA patients undergoing AF ablation present high prevalence of persistent AF. Freedom from AA after AF ablation is achieved in 42% of patients after a two-year follow-up. Patients with persistent AF recurrence have a three-fold higher risk of HFH and death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Department, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, Lugano CH-6900, Switzerland.
- Department of Cardiology, University of Naples Federico II, Naples, Italy.
- Cardiovascular Center, AZORG Hospital, Aalst, Belgium.
- Hôpital Cardiologique du Haut-Lévêque, CHU Bordeaux, L'Institut de Rythmologie et Modélisation Cardiaque (LIRYC), Université Bordeaux, Bordeaux, France.
- Department of Cardiology, University Hospital Antwerp, Edegem, Belgium.
- Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium.
ORCID-Profile: Daniele Faccenda, Marco Bergonti, Tom De Potter, Michel Haïssaguerre, Johan Saenen, Carlo De Asmundis, Giuseppe Ciconte, Marta De Riva, Michela Casella, Jacopo Costantino, Daniel Scherr, Mikael Laredo, Patrizio Mazzone, Avi Sabbag, Matteo Anselmino, Andrea Rossi, Matteo Bertini, Lia Crotti, Christian-Hendrik Heeger, Claudio Tondo, Elena Arbelo, Sebastiaan R D Piers, Maria L Caputo, Carlo Pappone, Domenico G Della Rocca, Olivier Van Leuven, Paolo Compagnucci, Tardu Özkartal, Raffaele Salerno, Chiara Pavone, Valeria Rella, Katharina I Gölly, Cristina Balla, Cristina Chimenti, Nicolas Johner, Esther Scheirlynck, Marco Schiavone, Cinzia Monaco, Giulio Conte
Zitieren
APA
Faccenda, D., Bergonti, M., De Potter, T., Haïssaguerre, M., Saenen, J., De Asmundis, C., Ciconte, G., De Riva, M., Casella, M., Costantino, J., Scherr, D., Laredo, M., Mazzone, P., Sabbag, A., Anselmino, M., Rossi, A., Bertini, M., Crotti, L., Heeger, C. H., …, & Conte, G. (2026). Catheter ablation of atrial fibrillation in transthyretin and light-chain cardiac amyloidosis: results from the multicentre AMYL-AF study. Europace, 28(6). https://doi.org/10.1093/europace/euag143
Vancouver
Faccenda D, Bergonti M, De Potter T, Haïssaguerre M, Saenen J, De Asmundis C, et al. Catheter ablation of atrial fibrillation in transthyretin and light-chain cardiac amyloidosis: results from the multicentre AMYL-AF study. Europace. 2026;28(6). doi:10.1093/europace/euag143
BibTeX
@article{Faccenda2026,
author = {Faccenda, Daniele and Bergonti, Marco and De Potter, Tom and Haïssaguerre, Michel and Saenen, Johan and De Asmundis, Carlo and Ciconte, Giuseppe and De Riva, Marta and Casella, Michela and Costantino, Jacopo and Scherr, Daniel and Laredo, Mikael and Mazzone, Patrizio and Sabbag, Avi and Anselmino, Matteo and Rossi, Andrea and Bertini, Matteo and Crotti, Lia and Heeger, Christian-Hendrik and Tondo, Claudio and Arbelo, Elena and Levinstein, Moises and Piers, Sebastiaan R D and Caputo, Maria L and Pappone, Carlo and Della Rocca, Domenico G and Van Leuven, Olivier and Compagnucci, Paolo and Özkartal, Tardu and Salerno, Raffaele and Pavone, Chiara and Rella, Valeria and Gölly, Katharina I and Gigli, Lorenzo and Balla, Cristina and Chimenti, Cristina and Johner, Nicolas and Laschera, Alessandro and Averaimo, Manuela and Scheirlynck, Esther and Schiavone, Marco and Monaco, Cinzia and Conte, Giulio},
title = {Catheter ablation of atrial fibrillation in transthyretin and light-chain cardiac amyloidosis: results from the multicentre AMYL-AF study},
journal = {Europace},
year = {2026},
volume = {28},
number = {6},
doi = {10.1093/europace/euag143}
}
EUVIMED